Department of Oncology, Rudong County Hospital of Traditional Chinese Medicine, Rudong, Jiangsu 226400, China.
The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210046, China.
Postgrad Med J. 2024 Jan 21;100(1180):96-105. doi: 10.1093/postmj/qgad102.
We aimed to investigate the pharmacological effects and mechanisms of the Aitongping formula for treating cancer pain.
We enrolled 60 cancer patients with Numeric Rating Scale above 4 and grouped them randomly as a Control group (N = 30) and a Patch group (N = 30). We also established bone cancer mice models via tumor implantation. And the animal groups were established as a Sham group, a tumor cell implantation (TCI) group, a TCI + Patch group, and a Patch group.
After the validation of successful tumor implantation, we identified candidate miRNAs and genes that were dysregulated in TCI mice and compared their expressions between different mice groups. We also observed the effect of Aitongping patch in vitro in mice primary microglia. The time to disease progression and cancer stability were prolonged by Aitongping patch in cancer patients. And the daily morphine dose was lower, and patients' quality of life was improved in the Patch group. Moreover, Aitongping patch alleviated cancer pain and inhibited microglia activation after the successful implantation of bone tumor in TCI mice. We also observed the dysregulation of miR-150-5p and chemokine CXC motif ligand 12 (CXCL12) mRNA in TCI mice. And CXCL12 was found to be targeted by miR-150-5p. Aitongping patch was found to upregulate miR-150-5p and downregulate CXCL12 in vivo and in vitro.
Aitongping patch could alleviate cancer pain via suppressing microglia activation, and the downregulation of miR-150-5p, as well as the upregulation of CXCL12 mRNA and protein, induced by tumor implantation or lipopolysaccharide stimulation, was restored by Aitongping treatment.
本研究旨在探讨癌痛的艾痛平方的药理作用及机制。
纳入 NRS 评分大于 4 的 60 例癌症患者,随机分为对照组(n=30)和贴剂组(n=30),同时建立骨癌小鼠模型。并将动物分为假手术组、肿瘤细胞植入组(TCI 组)、TCI+贴剂组和贴剂组。
成功验证肿瘤植入后,我们鉴定出 TCI 小鼠中失调的候选 miRNA 和基因,并比较了不同小鼠组之间的表达。我们还观察了艾痛平贴剂在小鼠原代小胶质细胞中的体外作用。艾痛平贴剂延长了癌症患者的疾病进展和癌症稳定时间,降低了每日吗啡剂量,提高了患者的生活质量。此外,艾痛平贴剂缓解了 TCI 小鼠骨肿瘤成功植入后的癌痛,并抑制了小胶质细胞的激活。我们还观察到 TCI 小鼠中 miR-150-5p 和趋化因子 CXC 基序配体 12(CXCL12)mRNA 表达失调,并且发现 CXCL12 是 miR-150-5p 的靶标。艾痛平贴剂在体内和体外均上调 miR-150-5p 并下调 CXCL12。
艾痛平贴剂通过抑制小胶质细胞激活缓解癌痛,肿瘤植入或脂多糖刺激引起的 miR-150-5p 下调和 CXCL12mRNA 和蛋白上调,通过艾痛平治疗得到恢复。